Clinical Trial Search

Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants

Primary: Percentage Change in Choroidal Neovascularization (CNV) Lesion Area Measured by Optical Coherence Tomography-Angiograph (OCT-A) From Baseline to Week 12 — -79.29 %…

Primary: Change in BCVA as Measured by the ETDRS Letter Score — -2.1; -0.4 Letters correctly read — p=0.0162

Primary: Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 48 — 7.03; 6.06; 5.89 scores on a scale — p=0.0009

Primary: Caliber of Choroidal New Vessel (CNV) — 43.53 micrometer

Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) — 5.5; 5.9 Letters correctly read

Primary: The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography) — -83.8; 52.6; 11.3; 55.4…

Primary: Mean Change in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score — 7.2 letters

Primary: Change From Baseline in CRT as Measured by SD-OCT on Day 29 — 44.0 μm

Primary: Change in Central Subfield Thickness From Baseline at 12 Months — -50.3 µm — p=<0.001

Primary: Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) — 94.4; 95.1; 95.9; 95.1 percentage of patients

Primary: Height (Amplitude) of Multifocal ERG Signal — 2.859 nanovolt/degree^2 — p=<0.05

Primary: Visual Acuity: Percentage of Patients Losing 3 or More Lines(15 Letters) of Visual Acuity From Baseline. — 80; 90 percent of participants

Primary: Vision — 0.16 logMAR

Primary: Number of Subjects With No Cells Observed Following Slit Lamp Examination From Baseline to Week 8 — 23; 21; 23; 21 Participants

Primary: Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) — 94.42; 95.62; 96.27; 95.56 Percentage of participants

Primary: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS)…

Primary: Percentage of Patients With Ocular Adverse Events (AEs) in the Study Eye — 48.5; 38.9 Percentage of Participants

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12 — 5.2; 5.6; 5.4…

Primary: Average Best-corrected Visual Acuity (BCVA) (Letters) Change up to Month 12 — 0.1; 1.0 Letters correctly read

Primary: Mean Change From Baseline in BCVA at Week 8 — 6.4; 6.5 Letters

Primary: Percentage of Participants With Stable Vision at Week 52 — 91.7; 91.2; 95.5 percentage of participants

Primary: Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score From Baseline to Week 100 - Last Observation Carried Forward (LOCF) — 58.7; 4.5 letters…

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 28 - Last Observation Carried Forward (LOCF) — 14.0; 3.9 Letters…

Primary: Visual Acuity - Continuous — -6.1; -1.6; 2.4 Letters seen

Primary: Visual Acuity (VA) — 8.51; 8.72; 8.67; 8.93 lines of VA

Primary: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) — 20; 20; 13; 13 Participants

Primary: Mean Change in Visual Acuity — 15.0; 5.6 letters — p=0.02

Primary: Percentage of Participants With Stable Vision at Week 52 — 94.8; 91.3; 96.0 percentage of participants

Primary: Macular Edema — 416 Microns